In research relating to atherosclerosis and cellular aging, researchers showed that the introduction of the NamPRT gene into aging human vascular smooth muscle cells delayed their deterioration and substantially lengthened cell lifespan.
Karl Normington, senior director of intellectual property and licensing at Sirtris, said: “In-licensing the exclusive rights to these patents is part of our overall strategy to build the broadest platform of technology and intellectual property for the development of sirtuin therapeutics for the treatment of diseases of aging.”